Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy

European Journal of Cancer
Clarice S. Groeneveld, Jacqueline Fontugne, Luc Cabel, Isabelle Bernard-Pierrot, François Radvanyi, Yves Allory, Aurélien de Reyniès
DOI
10.1016/j.ejca.2021.01.036
Teams / Core Facilities
Members